Primer registro nacional sobre la efectividad y seguridad de evolocumab en la práctica clínica en pacientes atendidos en cardiología en España. Estudio RETOSS-CARDIO

Escobar, 2018, Niveles óptimos de colesterol en los pacientes con dislipemia. Revisión sistemática de la evidencia, Semergen., 44, 42, 10.1016/j.semerg.2017.08.006 Del Pinto, 2019, Low density lipoprotein (LDL) cholesterol as a causal role for atherosclerotic disease: Potential role of PCSK9 inhibitors, High Blood Press Cardiovasc Prev., 26, 199, 10.1007/s40292-019-00323-7 Catapano, 2017, Guía ESC/EAS 2016 sobre el tratamiento de las dislipemias, Rev Esp Cardiol., 70, e1, 10.1016/j.recesp.2016.11.052 Tolonen, 2005, WHO. MONICA. Project. Prevalence, awareness and treatment of hypercholesterolaemia in 32 populations: Results from the WHO MONICA Project, Int J Epidemiol, 34, 181, 10.1093/ije/dyi056 Silverman, 2016, Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-analysis, JAMA., 316, 1289, 10.1001/jama.2016.13985 Barrios, 2008, Control de los factores de riesgo en los pacientes hipertensos con cardiopatía isquémica crónica atendidos en las consultas de cardiología. Estudio CINHTIA, Rev Clín Esp., 208, 400, 10.1157/13126342 Cordero, 2016, Tendencias en factores de riesgo y tratamientos de pacientes con cardiopatía isquémica estable atendidos en consultas de cardiología entre 2006 y 2014, Rev Esp Cardiol., 69, 401, 10.1016/j.recesp.2015.08.010 Galve, 2016, Grado de control lipídico en pacientes coronarios y medidas adoptadas por los médicos. Estudio REPAR, Rev Esp Cardiol., 69, 931, 10.1016/j.recesp.2016.02.013 Tsouka, 2018, Pharmacology of PCSK9 inhibitors: Current status and future perspectives, Curr Pharm Des., 24, 3622, 10.2174/1381612824666181010144823 Sabatine, 2017, Evolocumab and clinical outcomes in patients with cardiovascular disease, N Engl J Med., 376, 1713, 10.1056/NEJMoa1615664 Sabouret, 2019, PCSK9 inhibitors: What place in the management of dyslipidemia?, Presse Med., 48, 227, 10.1016/j.lpm.2019.01.009 Yao, 2019, Generalizability of the FOURIER trial to routine clinical care: Do trial participants represent patients in everyday practice?, Am Heart J., 209, 54, 10.1016/j.ahj.2018.09.015 Stoekenbroek, 2018, PCSK9 inhibitors in clinical practice: Delivering on the promise?, Atherosclerosis., 270, 205, 10.1016/j.atherosclerosis.2017.11.027 Cordero, 2019, Experiencia inicial en la práctica clínica con los inhibidores del PCSK-9 para las indicaciones actuales de financiación en España, Rev Esp Cardiol., 72, 968, 10.1016/j.recesp.2019.03.019 Elamin, 2019, Potential use of PCSK9 inhibitors as a secondary preventative measure for cardiovascular disease following acute coronary syndrome: A UK real-world study, Postgrad Med J., 95, 61, 10.1136/postgradmedj-2018-136171 Fairman, 2017, Real-world use of PCSK-9 inhibitors by early adopters: Cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice, Ther Clin Risk Manag., 13, 957, 10.2147/TCRM.S143008 Hovingh, 2017, Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia, J Clin Lipidol., 11, 1448, 10.1016/j.jacl.2017.09.003 Hines, 2018, Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors, Vasc Health Risk Manag., 14, 409, 10.2147/VHRM.S180496 Gürgöze, 2019, Adverse events associated with PCSK9 inhibitors: A real-world experience, Clin Pharmacol Ther., 105, 496, 10.1002/cpt.1193 Barrios, 2020, Primer registro nacional sobre la efectividad y seguridad de evolocumab en la práctica clínica en unidades de cardiología en España. Estudio RETOSS-CARDIO, Rev Esp Cardiol, 10.1016/j.recesp.2019.11.014 Ministerio de Sanidad, Servicios Sociales e Igualdad. Agencia Española de Medicamentos y Productos Sanitarios. Informe de posicionamiento terapéutico de evolocumab (Repatha®) en hipercolesterolemia (V1/03032016). Publicado el 3 de marzo de 2016. Disponible en: https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT-evolocumab-repatha.pdf. Stone, 2014, 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Circulation., 129, S1, 10.1161/01.cir.0000437738.63853.7a Kosmas, 2018, Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia, Patient Prefer Adherence., 12, 2263, 10.2147/PPA.S149423 Cannon, 2017, Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease, JAMA Cardiol., 2, 959, 10.1001/jamacardio.2017.2289 Zamora, 2018, Número de pacientes candidatos a recibir inhibidores de la PCSK9 según datos de 2,5 millones de participantes de la práctica clínica real, Rev Esp Cardiol., 71, 1010, 10.1016/j.recesp.2017.11.006 Agencia Europea del Medicamento (European Medicines Agency; EMA). Repatha®, Ficha técnica o resumen de las características del producto. Actualizado el 13 de mayo de 2019. Disponible en: https://www.ema.europa.eu/en/documents/product-information/repatha-epar-product-information_es.pdf. Kohli, 2017, Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: Lipid clinic experience in 2 contrasting UK centres, Int J Clin Pract., 71 Stroes, 2018, Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies, Clin Cardiol., 41, 1328, 10.1002/clc.23049 Raal, 2015, PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): A randomised, double-blind, placebo-controlled trial, Lancet., 385, 331, 10.1016/S0140-6736(14)61399-4 Cho, 2018, Persistent safety and efficacy of evolocumab in patients with statin intolerance: A subset analysis of the OSLER open-label extension studies, Cardiovasc Drugs Ther., 32, 365, 10.1007/s10557-018-6817-7 Corsini, 2019, Statin-associated muscle symptoms: Is proprotein convertase subtilisin/kexin type 9 inhibitors a therapeutic option?, Eur Heart J Suppl., 21, B48, 10.1093/eurheartj/suz007 Knickelbine, 2019, A systematic approach for successful PCSK9 inhibitor prescribing in clinical practice, J Clin Lipidol., 13, 265, 10.1016/j.jacl.2019.01.005 Anguita Sánchez, 2016, Necesidades no cubiertas con el tratamiento hipolipemiante oral: documento de posición de la Sociedad Española de Cardiología, Rev Esp Cardiol., 69, 1083, 10.1016/j.recesp.2016.05.013 Baum, 2017, PCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payers, Clin Cardiol., 40, 243, 10.1002/clc.22713 Boccara, 2017, Practical considerations for the use of subcutaneous treatment in the management of dyslipidaemia, Adv Ther., 34, 1876, 10.1007/s12325-017-0586-8 Robinson, 2019, Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit, J Clin Lipidol., 13, 525, 10.1016/j.jacl.2019.05.005 Escobar, 2018, Coste-efectividad del evolocumab, Rev Esp Cardiol., 71, 1089, 10.1016/j.recesp.2018.04.028